Shares of Jaguar Animal Health Inc (NASDAQ:JAGX) have been given a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company.
Brokerages have set a one year consensus price target of $6.75 for the company and are anticipating that the company will post ($0.40) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Jaguar Animal Health an industry rank of 92 out of 265 based on the ratings given to related companies.
Several brokerages recently weighed in on JAGX. Zacks Investment Research downgraded shares of Jaguar Animal Health from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. Aegis reaffirmed a “buy” rating and set a $10.00 target price on shares of Jaguar Animal Health in a research note on Monday, June 13th.
Shares of Jaguar Animal Health (NASDAQ:JAGX) opened at 1.28 on Wednesday. The stock’s 50 day moving average is $1.28 and its 200 day moving average is $1.58. The firm’s market capitalization is $14.23 million. Jaguar Animal Health has a 1-year low of $1.09 and a 1-year high of $4.70.
About Jaguar Animal Health
Jaguar Animal Health, Inc is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over eight indications across various species and non-prescription products targeting over seven species.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Animal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.